Y-90

North Star Vascular & Interventional Opens New Center in Minneapolis

Retrieved on: 
Wednesday, December 20, 2023
Technology, FDA, Health, Robotics, Other Health, Radiology, Surgery, Oncology, Practice Management, Medical Devices, Managed Care, General Health, Hospitals, Health Technology, Patient, Google Images, Varicocele, Artery, Pain management, Peripheral artery disease, Risk, Advocate Christ Medical Center, Knee, Physician, Uterine fibroid, Vascular disease, Intervention, Male, Infertility, Kidney disease, Chronic pain, Thyroid disease, Osteoarthritis, MBA, MD, Vein, Cancer, GE HealthCare, University, Moyamoya disease, Neoplasm, Rush University Medical Center, Fibroid, Interventional radiology, Liver cancer, Hospital-acquired infection, Pelvic congestion syndrome, Radiation, Y-90, Medical imaging

The field of vascular and interventional radiology is growing, and three area physicians have opened an outpatient center to provide viable alternatives to hospital-based surgery in Golden Valley.

Key Points: 
  • The field of vascular and interventional radiology is growing, and three area physicians have opened an outpatient center to provide viable alternatives to hospital-based surgery in Golden Valley.
  • North Star Vascular & Interventional (NSVI) offers minimally invasive procedures to treat health conditions such as peripheral artery and venous disease, cancer, enlarged prostate, uterine fibroids and more.
  • Jafar Golzarian, MD, FSIR, professor emeritus of interventional radiology at the University of Minnesota Medical School, has authored more than 400 academic articles and national and international lectures on interventional radiology.
  • Bulent Arslan, MD, FSIR is a Professor of Radiology and Chief of Interventional Radiology at the Rush University Medical Center in Chicago.

Precision IR Performs First Outpatient Y-90 Radioembolization Procedure in an Office-Based Lab in Michigan

Retrieved on: 
Friday, June 2, 2023
Biotechnology, Health, Radiology, Practice Management, Oncology, P.C, Osteoarthritis, Radiation, Y-90, Hepatic artery proper, Half-life, Neoplasm, Liver tumor, Journal of Vascular and Interventional Radiology, Cancer, Prostate, Precision, Liver cancer, Blood, Knee pain, Interventional radiology, Go (programming language), Hospital, Patient, Observation, Growth, OBL, Trauma, Liver, Medical imaging

Precision IR, a Division of Michigan Healthcare Professionals, P.C., a medical practice specializing in vascular and interventional radiology, performed the first outpatient OBL (office-based lab) Y-90 radioembolization procedure in Michigan on Thursday, May 25, 2023.

Key Points: 
  • Precision IR, a Division of Michigan Healthcare Professionals, P.C., a medical practice specializing in vascular and interventional radiology, performed the first outpatient OBL (office-based lab) Y-90 radioembolization procedure in Michigan on Thursday, May 25, 2023.
  • To perform the procedure in an OBL setting, the facility must have the required imaging equipment and procedure rooms, along with the processes to safely handle nuclear materials.
  • Clinical experience has shown that the vast majority of Y-90 radioembolization patients do not need to be kept overnight for observation; they are able to return home shortly after the two-hour procedure.
  • “But cancer patients appreciate the option of having their treatment in a more relaxed and customer-focused environment.”
    Precision IR is now scheduling Y-90 radioembolization patients.

Bruce Power to explore production of cancer-fighting medical isotope yttrium-90 for global distribution

Retrieved on: 
Monday, October 3, 2022
YouTube, Y-90, Cancer, Saugeen Ojibway Nation Territory, Liver cancer, Medicine, IPS, Society, Saugeen First Nation, LinkedIn, Business development, Ojibwe, Twitter, Interventional oncology, Instagram, Boston Scientific, MOU, Partnership, TheraSphere, SON, TC Energy, Leadership, Electricity, Environment, Microparticle, Patient, Power, Bruce Power, OMERS, GLOBE, Medical imaging, Lithium, Facebook, Isotope, Isogenic human disease models

Medical isotopes save lives and Ontario is primed to become an isotope superpower, said Ontarios Energy Minister Todd Smith.

Key Points: 
  • Medical isotopes save lives and Ontario is primed to become an isotope superpower, said Ontarios Energy Minister Todd Smith.
  • Additionally, Bruce Power will soon become the first nuclear power reactor operator to commercially produce lutetium-177 through an innovative Isotope Production System (IPS).
  • The IPS is a first-of-its-kind solution to produce short-lived medical isotopes in a commercial reactor and will provide unprecedented capacity, redundancy and scale for medical isotope production.
  • Isogen will also work with Bruce Power and Boston Scientific on the feasibility of yttrium-90 production using the IPS.

Global Emerging Isotopes Pipeline Analysis and Market Forecast to 2029 - ResearchAndMarkets.com

Retrieved on: 
Monday, July 25, 2022
Radiology, Health, Oncology, Hospital, Y-90, GEP-NET, Lutetium (177Lu) oxodotreotide, Diagnosis, Prostate cancer, University, Isotope, Prostate, Medicine, Cancer, Academy, Kidney cancer, Pharmaceutical industry

The "Emerging Isotopes Pipeline Analysis and Global Market - Forecast To 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Emerging Isotopes Pipeline Analysis and Global Market - Forecast To 2029" report has been added to ResearchAndMarkets.com's offering.
  • The pipeline focuses on diagnostic isotopes (Ga-68, Zr-89, Cu-64 and Pb-203) and therapeutic isotopes (Ac-225, Pb-212, At-211, Ra-223, Th-227, Lu-177, Y-90, Re-188, Re-186, Cu-67, and Ho-166).
  • The pipeline analysis covers detailed analysis of name of candidates, list of companies, universities, and hospitals that are developing these agents, phase of development, nature of molecule, targets, and indications.
  • This report enables Pharmaceutical/Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the emerging isotopes global market.

QSAM Biosciences Receives Third U.S. Patent for Clinical-Stage Radiopharmaceutical Drug Candidate CycloSam®

Retrieved on: 
Wednesday, July 13, 2022
Technology, Bone, Clinical trial, Radiation, News, Intention, Notice, Company, Y-90, CEO, GLOBE, Cleveland, Patent, Time, Radiopharmaceutical, QSAM, Risk, FDA, Dog, Cancer, Haematopoietic system, Cleveland Clinic, OTCQB, Pharmaceutical industry, Medical imaging

This patent covers both formulation and preparation of CycloSam in the U.S. with DOTMP kit formulations for radioisotope delivery targeting bone tumors, as well the high-dosage use of the radiopharmaceutical to perform bone marrow ablations.

Key Points: 
  • This patent covers both formulation and preparation of CycloSam in the U.S. with DOTMP kit formulations for radioisotope delivery targeting bone tumors, as well the high-dosage use of the radiopharmaceutical to perform bone marrow ablations.
  • The kit itself is designed to provide convenient and reproducible preparation of the drug with better delivery and higher purity for each specific formulation.
  • This patent issuance marks our third granted patent in the United States and further strengthens our IP estate, consisting of 14 patents among three distinct patent families.
  • QSAM Biosciences, Inc. is developing next-generation nuclear medicines for the treatment of cancer and related diseases.

DGAP-News: Eckert & Ziegler Extends Supply Agreement with Sirtex Medical to Chinese Market

Retrieved on: 
Friday, April 1, 2022
NICE, Nuclear medicine, TecDAX, Radiopharmaceutical, Liver, III, Growth, Mortality, II, Colorectal cancer, Y-90, News, DGAP, CMC, Deutsch, National Institute, Death, ISIN, SIRT, Liver cancer, Disease, Isotope, GMP, Partnership, Security (finance), Pharmaceutical industry, Sirtex

Eckert & Ziegler AG (ISIN DE0005659700, TecDAX) and Sirtex Medical (Sirtex) have extended their long-term supply agreement for the use of yttrium-90 in Sirtex microspheres for the treatment of liver cancer to the Chinese market.

Key Points: 
  • Eckert & Ziegler AG (ISIN DE0005659700, TecDAX) and Sirtex Medical (Sirtex) have extended their long-term supply agreement for the use of yttrium-90 in Sirtex microspheres for the treatment of liver cancer to the Chinese market.
  • From its production facilities in Braunschweig and Boston (MA), USA, Eckert & Ziegler supplies the Sirtex sites in Frankfurt, Boston, and Singapore with yttrium-90.
  • "The signing of this supply agreement reinforces the already strong relationship between the two companies as Sirtex enters the Chinese market", adds Grant Spindler, Global Head of Operations at Sirtex Medical Limited.
  • In Jintan (China), Eckert & Ziegler is investing up to EUR 50 million in the construction of a production facility for radiopharmaceuticals.

Bruce Power establishes new Ontario-based medical isotope hub to assist in global cancer fight

Retrieved on: 
Thursday, March 10, 2022
Government, IPS, EOI, University of Toronto, University Health Network, University, Hub, Physician, Medicine, Department, Saugeen Ojibway Nation Territory, Partnership, Saugeen First Nation, Cancer, Center, Y-90, Princess Margaret Cancer Centre, Princess Margaret, Countess of Snowdon, Radiation therapy, Health, Policy, Hospital, Leadership, GLOBE, Chippewas of Nawash Unceded First Nation, Patient, Bruce Power, SON, Economic development, Knowledge, Liver cancer, Nuclear energy, Organization, Program, CEO, ITM, Nuclear medicine, Oncology, Rare-earth element, Medical imaging, Lithium, Renewable energy, Isotope, Isogenic human disease models, Ojibwe

The new Ontario Isotope Innovation Hub will position Ontario as a global leader in the production of life-saving medical isotopes and ensure that the province is at the forefront of isotope research, development and innovation.

Key Points: 
  • The new Ontario Isotope Innovation Hub will position Ontario as a global leader in the production of life-saving medical isotopes and ensure that the province is at the forefront of isotope research, development and innovation.
  • Kinectrics Centre for Medical Isotopes & Nuclear Chemistry will transform innovative ideas and concepts into new Made-in-Ontario medical isotope products and services.
  • The Ontario Isotope Innovation Hub is a huge step forward in ensuring our province continues to lead when it comes to this important work.
  • The EOI will leverage the newly-installed, Made-in-Ontario, Isotope Production System (IPS) at Bruce Power, designed and manufactured by Isogen, which will be a cornerstone of the hub.

Global Nuclear Medicine Markets, Forecast & Opportunities Report 2021-2026 - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 23, 2021
General Health, Health, Oncology, Other Health, Adoption, Forecast, Application, Therapy, Cancer, Patient, Biomarker, Nuclear medicine, Isotopes of molybdenum, Y-90, Lymphoma, F-18, Radiopharmaceutical, Prevalence, Disease, Bone metastasis, Research, Radiation, Incidence, Molecular imaging, X-ray, Medical imaging

The "Global Nuclear Medicine Market, By Type, By Diagnostic Nuclear Medicine, By Therapeutic Nuclear Medicine, By Application, By Diagnostic Applications, By Therapeutic Applications, By End User, By Region, Forecast & Opportunities, 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Nuclear Medicine Market, By Type, By Diagnostic Nuclear Medicine, By Therapeutic Nuclear Medicine, By Application, By Diagnostic Applications, By Therapeutic Applications, By End User, By Region, Forecast & Opportunities, 2026" report has been added to ResearchAndMarkets.com's offering.
  • Apart from above mentioned growth factors, the global nuclear medicine market also faces some restrains.
  • The global nuclear medicine market is segmented based on therapy, type, application, therapeutics, route of administration, end-user and region.
  • Based on type, the nuclear medicine market is segmented into Diagnostic Nuclear Medicine, Therapeutic Nuclear Medicine, Brachytherapy Isotopes.